When people talk about personalized medicine, they usually talk about stratification, the use of biomarkers to identify a subset of patients expected to respond to a specific therapeutic agent. But a
The EU is to fund a 14-member group of biotech companies and clinical centers in Europe and the U.S. in an effort to develop a more sophisticated, personalized, approach to the development of cancer v
BioVest International, an emerging leader in active personalised immunotherapies and majority-owned subsidiary of Accentia Biopharmaceuticals, has named Dr Eduardo Sotomayor to its scientific advisory
After 18 years of development, Biovest International plans to file applications for marketing approval for its personalized therapeutic cancer vaccine BiovaxID by the end of 2012 in Canada, the EU and